New Research Uncovers Immune Mechanism Driving Radiation-Induced Lung Injury Researchers at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, have identified an immune signaling pathway that may contribute to…
BrightFocus Foundation’s $330 Million Research Investment Generates Eightfold Increase in Follow-On Funding, Assessment Finds BrightFocus Foundation, a nonprofit organization dedicated to advancing research into Alzheimer’s disease, macular degeneration, and glaucoma, has reported significant returns from its long-term investment in early-stage…
Immunis Named Semifinalist in National Academy of Medicine’s Healthy Longevity Global Competition for Muscle Health Innovation Immunis, Inc., a clinical-stage biotechnology company developing multi-active biologics designed to restore muscle health and function, has been selected as a semifinalist in the…
TG Therapeutics Publishes Five-Year Comparative Analysis Showing Favorable Long-Term Outcomes for BRIUMVI in Relapsing Multiple Sclerosis TG Therapeutics, Inc. has announced the publication of results from a five-year matching-adjusted indirect comparison (MAIC) evaluating the long-term efficacy of BRIUMVI® (ublituximab-xiiy) against…
BIOMAG™-LL Study Completes Enrollment for Longer Freesolve™ Magnesium Scaffolds Teleflex Incorporated (NYSE: TFX), a global provider of medical technologies, has announced the successful completion of patient enrollment in the BIOMAG™-LL Clinical Study, which is evaluating the safety and clinical performance…
bioAffinity Technologies Closes $4 Million Registered Direct Offering to Support CyPath® Lung Sales and Corporate Operations bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, has announced…
Secretome Therapeutics to Present Phase 1 Clinical Data for STM-01 in Heart Failure With Preserved Ejection Fraction Secretome Therapeutics, a clinical-stage biotechnology company developing innovative therapies derived from neonatal cardiac progenitor cells (nCPCs), has announced that clinical data from its…
Life Sciences BC Selects 2027 Investor Readiness Program Cohort to Support Growth of Emerging Life Sciences Companies Life Sciences BC (LSBC) has announced the companies selected to participate in its 2027 Investor Readiness Program (IRP), a six-month initiative designed to…
Invivoscribe Launches Complete LymphoTrack Flex Suite for NGS-Based Clonality and MRD Analysis Invivoscribe, a global provider of precision diagnostics and measurable residual disease (MRD) testing solutions, has announced the launch of the complete LymphoTrack Flex suite, an integrated next-generation sequencing…
BioCentury Opens Registration for 2027 Grand Rounds Conference in Houston BioCentury has announced that registration is now open for the sixth edition of BioCentury Grand Rounds: US, a translational science-focused conference scheduled for April 12–14, 2027, in Houston, Texas. The…
Travere to Present New FILSPARI Data in IgA Nephropathy and FSGS at ASN Kidney Week 2026 Travere Therapeutics, Inc. (Nasdaq: TVTX) is set to present nine new data analyses, including five oral presentations, at the American Society of Nephrology (ASN)…
Orano Med Inaugurates ATLab Valenciennes, Europe’s First Industrial-Scale Facility for Lead-212 Targeted Alpha Therapies Orano Med, a subsidiary of the Orano Group and a pioneer in targeted alpha therapies for cancer, has inaugurated ATLab Valenciennes, an industrial-scale pharmaceutical manufacturing facility…